Go Deep
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,302 | 58.6 | 2.48 | 0.01 | 394.00 |
| Oct 2026 | 22,190 | 58.6 | 2.48 | 0.01 | 394.00 |
| Oct 2026 | 22,259 | 53.9 | 2.27 | 0.01 | 360.90 |
Ind-Swift Laboratories Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,914,539,000.0 | 1,697,868,000.0 | 1,508,534,000.0 | 1,526,442,000.0 |
| Net Profit | 246,841,000.0 | 151,121,000.0 | 95,383,000.0 | 79,902,000.0 |
| EPS | 2.8 | 1.8 | 1.2 | 1.0 |
Ind-Swift Laboratories Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 6,258,841,000.0 | 5,617,125,000.0 | 17,091,499,000.0 | 12,073,100,000.0 | — |
| Net Profit | 431,249,000.0 | 2,504,766,000.0 | 5,387,502,000.0 | 475,966,000.0 | — |
| EPS | 5.2 | 37.2 | 91.2 | -4.3 | — |
Ind-Swift Laboratories Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 16,733,498,000.0 | 14,383,386,000.0 | 14,604,338,000.0 | 18,240,640,000.0 | — |
| Total Liabilities | 2,893,838,000.0 | 2,653,737,000.0 | 6,483,669,000.0 | 11,421,333,000.0 | — |
| Total Equity | 13,840,235,000.0 | 11,729,997,000.0 | 8,120,840,000.0 | 6,819,307,000.0 | — |
Owes vs Owns
Ind-Swift Laboratories Limited owed ₹0.17 for every ₹1 it owned in Mar 2026, down from ₹0.63 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.18× | 0.44× | 0.63× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ind-Swift Laboratories Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 26.4%Receivables 11.9%Inventory 8.8%Fixed assets (tangible) 18.2%Intangible assets 1.6%Long-term investments 1.2%Other assets 31.9%
How it's funded — Mar 2026
Long-term debt 0.7%Payables 8.7%Other liabilities 7.5%Shareholders' equity 82.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 441.8 | 464.5 | 477.8 | 23.2 |
| Receivables | 198.5 | 164.5 | 313.0 | 505.3 |
| Inventory | 147.9 | 114.2 | 74.5 | 438.6 |
| Fixed assets (tangible) | 304.7 | 265.7 | 230.9 | 593.7 |
| Intangible assets | 27.5 | 10.7 | 10.5 | 0.0 |
| Long-term investments | 19.9 | 1.7 | 1.8 | 30.3 |
| Other assets | 533.1 | 417.1 | 351.9 | 232.9 |
| Liabilities & equity | ||||
| Short-term debt | 5.6 | 7.0 | 17.8 | 108.9 |
| Long-term debt | 12.1 | 25.7 | 198.7 | 752.6 |
| Payables | 145.9 | 110.2 | 292.9 | 204.0 |
| Other liabilities | 125.8 | 122.4 | 138.9 | 76.6 |
| Shareholders' equity | 1,384.0 | 1,173.0 | 812.1 | 681.9 |
| Net tangible assets | 1,356.6 | 1,162.3 | 801.6 | 681.9 |
Ind-Swift Laboratories Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -681,685,000.0 | -286,903,000.0 | -1,869,836,000.0 | 1,946,196,000.0 | — |
| Investing Activities | -726,832,000.0 | -1,131,252,000.0 | -271,532,000.0 | -133,683,000.0 | — |
| Financing Activities | 1,418,086,000.0 | 724,214,000.0 | 6,573,541,000.0 | -1,856,574,000.0 | — |